BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 16143255)

  • 1. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N
    J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation.
    Morton JM; Aboyoun CL; Malouf MA; Plit ML; Glanville AR
    J Heart Lung Transplant; 2004 Sep; 23(9):1035-9. PubMed ID: 15454168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan.
    Chou NK; Chen RJ; Ko WJ; Lin HL; Yu SY; Chen YS; Hsu RB; Lee CM; Lin FY; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2393-5. PubMed ID: 15561260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection?
    el Gamel A; Keevil B; Rahman A; Campbell C; Deiraniya A; Yonan N
    J Heart Lung Transplant; 1997 Mar; 16(3):268-74. PubMed ID: 9087869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
    Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
    Marcén R; Villafruela JJ; Pascual J; Teruel JL; Ocaña J; Tenorio MT; Burgos FJ; Ortuño J
    Nephrol Dial Transplant; 2005 Apr; 20(4):803-10. PubMed ID: 15687111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
    Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.